UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000018749
Receipt No. R000021233
Scientific Title The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD
Date of disclosure of the study information 2015/08/21
Last modified on 2020/08/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD
Acronym The effects of galantamine administration on brain network topology in patients with Alzheimer's disease
Scientific Title The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of AD
Scientific Title:Acronym The effects of galantamine administration on brain network topology in patients with Alzheimer's disease
Region
Japan

Condition
Condition mild to moderate Alzhiemer's disease
Classification by specialty
Neurology Psychiatry
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The aim of the study is to clarify whether ph-rsfcMRI could provide a possible biomarker for evaluation of galantamine treatment and prediction of response to pharmacological treatment in AD.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Short-term effects of galantamine onto brain network topology, especially, difference in brain network states between galantamine administration and placebo administration.
Key secondary outcomes For the participants who underwent 4W galantamine administration, we will evaluate long-term effects of galantamine as follows.
1.Differences in network topology parameters between galantamine responders (as defined in this protocol) and non-responders. Two types of comparisons will be made: (1) comparison of galantamine effects versus placebo effects before 4W galantamine administration and (2) effects of placebo administration before and after the 4W galantamine administration.
2.Correlation analysis between changes in network topology parameters and changes in ADAS-J cog scores and sub-scores before and after the 4W galantamine administration.
3.Correlation analysis between changes in network topology parameters and changes in CGI-I before and after the 4W galantamine administration.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 galantamine 4 mg/day, 1 day
or
galantamine 4 mg/day, 4 week
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria A diagnosis of probable AD according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDSADRDA) with Mini-Mental State Examination (MMSE) scores between 10 and 25.
Key exclusion criteria 1) Co-existing other neurodegenerative disease.
2) A history indicating excessive nicotine or alcohol intake (>0.5 packs of cigarettes, >4 glasses of an alcoholic substance a day), a severe allergy to pharmacological substances or their constitutive compounds, or the use of any experimental medication within 3months prior to the enrolment in the trial.
3) Patients with cardiovascular disease (e.g. myocardial infarction, valvulitis, or cardiomyopathy) or electrolyte imbalance (e.g. hypokalaemia).
4) Patients with severe liver dysfunction (Child-Pugh score of C) or severe renal dysfunction.
5) Exclusion criteria to MRI: presence of a pacemaker, metallic implants in high-risk areas (i.e. aneurysm clips) and a history of claustrophobia.
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Takashi
Middle name
Last name Hanakawa
Organization Natinal Center of Neurology and Psychiatry
Division name Integrative Brain Imaging Center
Zip code 187-8551
Address 4-1-1 Ogawahigashi, Kodaira, Tokyo
TEL 042-346-2206
Email hanakawa@ncnp.go.jp

Public contact
Name of contact person
1st name Mayumi
Middle name
Last name Inoue
Organization Natinal Center of Neurology and Psychiatry
Division name Integrative Brain Imaging Center
Zip code 187-8551
Address -4-1-1 Ogawahigashi, Kodaira, Tokyo
TEL 042-346-2206
Homepage URL
Email mainoue@ncnp.go.jp

Sponsor
Institute Natinal Center of Neurology and Psychiatry
Institute
Department

Funding Source
Organization Janssen Pharmaceutical K.K.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization National Center of Neurology and Psychiatry Clinical Research Review Board
Address 4-1-1 Ogawa-Higashi, Kodaira,Tokyo 187-8551, Japan
Tel 042-341-2712-7828
Email rinri-jimu@ncnp.go.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 08 Month 21 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 9
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 03 Month 31 Day
Date of IRB
2020 Year 02 Month 17 Day
Anticipated trial start date
2015 Year 04 Month 01 Day
Last follow-up date
2020 Year 04 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 08 Month 21 Day
Last modified on
2020 Year 08 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021233

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.